An open-label,prospective, randomized pilot study to evaluate the efficacy, safety and
tolerability of paeoniflorin, for the treatment of autoimmune hepatitis (AIH) with mild
necroinflammatory activity on liver biopsy.
Drug: Paeoniflorin + phosphatidylcholine or silymarin
Drug: Phosphatidylcholine or silymarin
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT02878863
Ages eligible for Study
20 Years to 70 Years
Genders eligible for Study
Accepts Healthy Volunteers
Patients aged 20-70 years;
Diagnosed with AIH or primary biliary cirrhosis-autoimmune hepatitis overlap syndrome based on liver biopsy results and without indication of immunosuppressive therapy;
High levels of alanine aminotransferase (ALT) or aspartate aminotransferase (AST)(1-3 X ULN);
Some people want to consult their doctor before considering participation in a clinical trial. This is absolutely normal as your doctor should know your medical history and should be able to advise you. If you want you can easily share the information for this trial with your doctor by clicking on the button below.